Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created ...

Patients have reported dental issues like tooth decay and dry mouth after taking GLP-1s like Ozempic for weight loss, though no scientific evidence confirms this connection.

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

The agreement unites two brands that are popular with Gen Z and helps the buyer diversify its supply chain outside of China. Pipeline operator Williams will seek to build two natural-gas supply lines ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

NRG's Stock Is a Top Gainer. How Does It Really Make Money? The company looks more like a risky energy trader than a simple power producer. Ethan Allen Faces Fewer Tariffs Than Rivals, but Consumer ...